AbbVie zumilokibart Phase 2 study meets primary endpoint in atopic dermatitis
The mid-dose regimen was selected for Phase 3 development, the company said.
GetSignal AbbVie Inc. ABBV
AbbVie said on September 30, 2026 that primary results from the Phase 2 APEX Part B study of zumilokibart in adults with moderate to severe atopic dermatitis will be presented as a late-breaker at EADV 2026 in Vienna.
The company said all three dose regimens met the primary endpoint, with significantly greater EASI-75 response rates than placebo at Week 16. The mid-dose regimen was selected for Phase 3 development.
Key facts
- Study
- APEX Part B, Phase 2
- Presentation
- Late-breaker at EADV 2026, Vienna
- Phase 3 regimen
- Mid-dose
Source: The company's release on PR Newswire, September 30, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
